Meng F, et al. - For neuralgia treatment, Researchers conducted a meta-analysis to assess the effectiveness and safety of botulinum toxin-A (BTX-A). Twelve randomized controlled trials (RCTs) comparing BTX-A treatment with saline for alleviating neuropathic pain were analyzed. At 4 weeks, the BTX-A group displayed significantly lower pain scores vs the saline group. BTX-A was not linked to any serious adverse events, but 14 out of 108 patients with trigeminal neuralgia experienced mild facial asymmetry after treatment with BTX-A. Findings thereby suggest that BTX-A could be a safe and effective treatment option for neuralgia.